Free Trial

Exact Sciences (EXAS) Financials

Exact Sciences logo
$43.67 -0.58 (-1.31%)
Closing price 04:00 PM Eastern
Extended Trading
$43.20 -0.47 (-1.06%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Exact Sciences

Annual Income Statements for Exact Sciences

This table shows Exact Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-158 -167 -114 -175 -213 -824 -596 -624 -204 -1,029
Consolidated Net Income / (Loss)
-158 -167 -114 -175 -213 -824 -596 -624 -204 -1,029
Net Income / (Loss) Continuing Operations
-158 -167 -114 -175 -213 -824 -596 -624 -204 -1,029
Total Pre-Tax Income
-158 -167 -115 -175 -406 -829 -843 -633 -202 -1,036
Total Operating Income
-159 -169 -118 -159 -234 -768 -856 -594 -215 -1,049
Total Gross Profit
15 54 188 338 660 1,137 1,308 1,423 1,762 1,919
Total Revenue
39 99 266 454 876 1,491 1,767 2,084 2,500 2,759
Operating Revenue
39 99 266 454 876 1,491 1,767 2,084 2,500 2,759
Total Cost of Revenue
25 45 78 117 217 354 459 661 738 840
Operating Cost of Revenue
25 45 78 117 217 354 459 661 738 840
Total Operating Expenses
174 223 306 497 893 1,905 2,164 2,016 1,977 2,967
Selling, General & Admin Expense
58 77 109 178 352 481 801 663 800 782
Marketing Expense
82 113 154 249 385 590 862 930 828 894
Research & Development Expense
34 33 42 67 140 554 386 394 427 431
Other Operating Expenses / (Income)
- - - 0.00 0.00 -24 0.00 13 -78 -9.20
Impairment Charge
- - - 0.00 0.00 210 20 16 0.62 869
Total Other Income / (Expense), net
1.27 1.81 3.73 -16 -173 -61 13 -39 13 13
Interest Expense
0.01 0.21 0.21 37 199 68 19 20 19 27
Other Income / (Expense), net
- - - - - 6.57 32 -19 - 40
Income Tax Expense
- - -0.19 0.09 -193 -5.46 -247 -9.06 2.40 -7.30
Basic Earnings per Share
($1.71) ($1.63) ($0.99) ($1.43) ($1.62) ($5.45) ($3.48) ($3.54) ($1.13) ($5.59)
Weighted Average Basic Shares Outstanding
92.14M 102.34M 115.68M 122.21M 131.26M 151.14M 171.35M 176.35M 180.14M 184.20M
Diluted Earnings per Share
($1.71) ($1.63) ($0.99) ($1.43) ($1.62) ($5.45) ($3.48) ($3.54) ($1.13) ($5.59)
Weighted Average Diluted Shares Outstanding
92.14M 102.34M 115.68M 122.21M 131.26M 151.14M 171.35M 176.35M 180.14M 184.20M
Weighted Average Basic & Diluted Shares Outstanding
92.14M 102.34M 115.68M 122.21M 131.26M 151.14M 178.22M - 181.53M 185.76M

Quarterly Income Statements for Exact Sciences

This table shows Exact Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-149 -128 -74 -81 0.79 -50 -110 -16 -38 -865
Consolidated Net Income / (Loss)
-149 -128 -74 -81 0.79 -50 -110 -16 -38 -865
Net Income / (Loss) Continuing Operations
-149 -128 -74 -81 0.79 -50 -110 -16 -38 -865
Total Pre-Tax Income
-152 -130 -72 -80 1.04 -50 -108 -14 -37 -876
Total Operating Income
-138 -119 -77 -77 6.85 -68 -107 -26 -39 -876
Total Gross Profit
375 319 446 465 460 392 467 509 513 429
Total Revenue
523 553 602 622 628 647 638 699 709 713
Operating Revenue
523 553 602 622 628 647 638 699 709 713
Total Cost of Revenue
148 234 157 157 169 255 170 190 196 284
Operating Cost of Revenue
148 234 157 157 169 255 170 190 196 284
Total Operating Expenses
513 438 523 542 453 460 574 536 552 1,306
Selling, General & Admin Expense
192 120 217 238 217 128 243 202 217 120
Marketing Expense
188 294 187 176 173 291 192 185 195 322
Research & Development Expense
91 95 95 104 111 116 111 121 100 100
Other Operating Expenses / (Income)
13 - 0.00 0.00 -72 -6.40 0.27 -3.80 -3.10 -2.57
Impairment Charge
5.95 3.43 0.07 0.55 0.00 - 4.45 8.15 19 838
Total Other Income / (Expense), net
-14 -11 4.60 -2.99 -5.81 17 -1.73 12 1.98 0.39
Interest Expense
5.24 5.41 -4.11 7.82 7.87 7.87 7.94 -0.11 9.61 9.58
Income Tax Expense
-3.12 -2.18 1.66 1.11 0.25 -0.61 1.81 1.46 0.81 -11
Basic Earnings per Share
($0.84) ($0.72) ($0.42) ($0.45) $0.00 ($0.26) ($0.60) ($0.09) ($0.21) ($4.69)
Weighted Average Basic Shares Outstanding
177.00M 176.35M 178.57M 180.20M 180.65M 180.14M 182.35M 184.31M 184.80M 184.20M
Weighted Average Diluted Shares Outstanding
177.00M 176.35M 180.85M 180.20M 184.08M 180.14M 184.53M 184.31M 184.80M 184.20M
Weighted Average Basic & Diluted Shares Outstanding
177.68M 0.00 180.85M - - 181.53M 184.53M 184.77M 185.08M 185.76M

Annual Cash Flow Statements for Exact Sciences

This table details how cash moves in and out of Exact Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
-17 7.79 29 83 17 1,314 -1,176 -73 367 -3.04
Net Cash From Operating Activities
-134 -130 -72 -69 -112 136 -102 -224 156 211
Net Cash From Continuing Operating Activities
-134 -130 -72 -69 -112 136 -102 -224 156 211
Net Income / (Loss) Continuing Operations
-158 -167 -114 -175 -213 -824 -596 -624 -204 -1,029
Consolidated Net Income / (Loss)
-158 -167 -114 -175 -213 -824 -596 -624 -204 -1,029
Depreciation Expense
7.60 11 15 21 34 70 85 100 114 120
Amortization Expense
0.94 -0.30 -0.55 29 14 96 95 97 92 95
Non-Cash Adjustments To Reconcile Net Income
17 25 36 58 300 843 449 297 173 1,094
Changes in Operating Assets and Liabilities, net
-1.85 1.45 -7.79 -0.91 -247 -49 -136 -95 -19 -69
Net Cash From Investing Activities
-65 -12 -161 -782 -124 -702 -1,082 74 50 -442
Net Cash From Continuing Investing Activities
-65 -12 -161 -782 -124 -702 -1,082 74 50 -442
Purchase of Property, Plant & Equipment
-20 -15 -48 -150 -173 -476 -194 -214 -125 -181
Acquisitions
-1.90 - -24 -18 -974 -6.66 -500 -15 -52 0.00
Purchase of Investments
-205 -190 -357 -1,193 -634 -1,106 -1,182 -174 -156 -467
Sale of Property, Plant & Equipment
- - - - - 0.00 0.00 25 0.00 0.00
Sale and/or Maturity of Investments
162 193 271 579 1,657 887 794 453 383 206
Other Investing Activities, net
- - -3.07 -0.58 -1.00 0.35 -0.74 -0.55 0.25 -0.23
Net Cash From Financing Activities
182 150 261 934 253 1,880 8.47 76 160 232
Net Cash From Continuing Financing Activities
182 150 261 934 253 1,880 8.47 76 160 232
Repayment of Debt
- - -0.20 0.00 -493 -151 -29 0.00 0.00 -68
Issuance of Debt
5.47 - 0.00 923 729 1,124 0.00 44 128 267
Issuance of Common Equity
177 150 261 12 17 907 38 32 32 33
Effect of Exchange Rate Changes
0.01 -0.22 - - 0.00 0.00 0.02 0.03 1.32 -3.29
Cash Interest Paid
0.10 0.21 0.20 4.64 5.13 9.38 11 12 19 28

Quarterly Cash Flow Statements for Exact Sciences

This table details how cash moves in and out of Exact Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
22 7.19 179 183 -9.75 15 -258 184 59 12
Net Cash From Operating Activities
-41 52 -38 100 24 70 -82 107 139 47
Net Cash From Continuing Operating Activities
-41 52 -38 100 24 70 -82 107 139 47
Net Income / (Loss) Continuing Operations
-149 -128 -74 -81 0.79 -50 -110 -16 -38 -865
Consolidated Net Income / (Loss)
-149 -128 -74 -81 0.79 -50 -110 -16 -38 -865
Depreciation Expense
25 27 27 28 29 31 31 30 30 29
Amortization Expense
24 23 23 23 23 23 23 23 24 24
Non-Cash Adjustments To Reconcile Net Income
89 63 51 73 5.20 44 75 53 73 893
Changes in Operating Assets and Liabilities, net
-30 67 -65 58 -34 21 -101 16 49 -34
Net Cash From Investing Activities
65 -58 83 66 -33 -67 -171 -147 -82 -42
Net Cash From Continuing Investing Activities
66 -58 83 66 -33 -67 -171 -147 -82 -42
Purchase of Property, Plant & Equipment
-45 -73 -29 -35 -25 -35 -38 -36 -26 -81
Acquisitions
1.37 -15 - - - -2.41 - - - 45
Purchase of Investments
-23 -45 -9.03 -48 -25 -75 -178 -148 -81 -60
Sale and/or Maturity of Investments
108 76 121 149 67 46 44 36 71 55
Net Cash From Financing Activities
0.24 10 134 16 0.09 10 -3.00 225 -0.23 10
Net Cash From Continuing Financing Activities
0.24 10 134 16 0.09 10 -3.00 225 -0.23 10
Repayment of Debt
-0.71 5.11 -5.34 -1.16 6.50 - -1.59 -48 - -18
Issuance of Debt
- -5.53 138 - -7.48 -2.27 0.00 254 -2.36 16
Issuance of Common Equity
0.94 11 - - - 15 - - - 13
Effect of Exchange Rate Changes
-2.43 3.21 0.55 0.06 -1.24 1.95 -1.14 -0.31 1.87 -3.72
Cash Interest Paid
5.62 0.77 6.44 0.94 11 0.60 11 1.18 9.14 6.73

Annual Balance Sheets for Exact Sciences

This table presents Exact Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
364 377 599 1,524 3,506 4,925 6,227 6,227 6,471 5,928
Total Current Assets
326 334 487 1,228 554 2,199 982 982 1,194 1,571
Cash & Equivalents
41 49 77 160 177 1,491 242 242 605 601
Short-Term Investments
266 262 347 964 146 349 390 390 172 437
Accounts Receivable
4.93 8.53 26 45 130 233 158 158 204 249
Inventories, net
6.68 6.83 26 39 62 92 118 118 127 162
Prepaid Expenses
7.38 7.11 10 19 38 33 74 74 86 122
Plant, Property, & Equipment, net
34 38 80 245 455 452 685 685 698 694
Total Noncurrent Assets
4.07 5.33 31 51 2,497 2,275 4,560 4,560 4,579 3,663
Goodwill
- - 24 17 1,203 1,238 2,346 2,346 2,367 2,367
Intangible Assets
- 1.55 - 29 1,144 847 1,956 1,956 1,890 1,010
Other Noncurrent Operating Assets
4.07 3.78 7.15 4.42 150 190 258 258 321 287
Total Liabilities & Shareholders' Equity
364 377 599 1,524 3,506 4,925 6,227 6,227 6,471 5,928
Total Liabilities
37 42 78 843 1,218 2,690 3,184 3,184 3,326 3,526
Total Current Liabilities
27 31 68 136 236 633 413 413 515 732
Short-Term Debt
0.17 0.17 0.18 0.01 0.83 314 - 0.00 50 249
Accounts Payable
3.31 0.71 16 28 26 36 75 75 79 90
Accrued Expenses
22 28 49 101 193 234 299 299 342 328
Other Current Liabilities
1.00 1.70 2.68 7.38 16 50 39 39 44 65
Total Noncurrent Liabilities
10 11 10 707 981 2,056 2,771 2,771 2,811 2,794
Long-Term Debt
4.79 4.63 4.27 689 828 1,884 2,236 2,236 2,314 2,321
Capital Lease Obligations
1.06 0.69 - - 119 121 182 182 161 157
Other Noncurrent Operating Liabilities
4.60 5.73 5.75 18 35 51 352 352 336 316
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
327 335 520 681 2,288 2,236 3,043 3,043 3,145 2,402
Total Preferred & Common Equity
327 335 520 681 2,288 2,236 3,043 3,043 3,145 2,402
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
327 335 520 681 2,288 2,236 3,043 3,043 3,145 2,402
Common Stock
906 1,082 1,382 1,718 3,408 4,281 6,313 6,313 6,613 6,901
Retained Earnings
-579 -746 -861 -1,036 -1,120 -2,046 -3,265 -3,265 -3,469 -4,498
Accumulated Other Comprehensive Income / (Loss)
-0.43 -0.42 -0.75 -1.42 -0.10 0.53 -5.24 -5.24 1.43 -0.94

Quarterly Balance Sheets for Exact Sciences

This table presents Exact Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
6,227 6,421 6,376 6,673 6,749
Total Current Assets
982 1,148 1,120 1,452 1,533
Cash & Equivalents
242 595 347 530 589
Short-Term Investments
390 140 305 417 432
Accounts Receivable
158 199 241 264 265
Inventories, net
118 133 129 127 137
Prepaid Expenses
74 82 99 114 110
Plant, Property, & Equipment, net
685 692 702 703 690
Total Noncurrent Assets
4,560 4,580 4,554 4,518 4,525
Goodwill
2,346 2,367 2,367 2,367 2,367
Intangible Assets
1,956 1,913 1,867 1,843 1,864
Other Noncurrent Operating Assets
258 300 320 307 293
Total Liabilities & Shareholders' Equity
6,227 6,421 6,376 6,673 6,749
Total Liabilities
3,184 3,300 3,244 3,481 3,538
Total Current Liabilities
413 477 685 669 724
Short-Term Debt
0.00 50 299 249 249
Accounts Payable
75 74 60 53 98
Accrued Expenses
299 310 265 303 314
Other Current Liabilities
39 43 61 64 63
Total Noncurrent Liabilities
2,771 2,823 2,559 2,812 2,814
Long-Term Debt
2,236 2,313 2,067 2,318 2,319
Capital Lease Obligations
182 168 162 168 163
Other Noncurrent Operating Liabilities
352 342 329 327 332
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
3,043 3,121 3,133 3,192 3,211
Total Preferred & Common Equity
3,043 3,121 3,133 3,192 3,211
Preferred Stock
0.00 0.00 0.00 0.00 0.00
Total Common Equity
3,043 3,121 3,133 3,192 3,211
Common Stock
6,313 6,542 6,713 6,789 6,839
Retained Earnings
-3,265 -3,419 -3,579 -3,595 -3,633
Accumulated Other Comprehensive Income / (Loss)
-5.24 -1.54 -0.50 -0.94 4.63

Annual Metrics and Ratios for Exact Sciences

This table displays calculated financial ratios and metrics derived from Exact Sciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
2,093.38% 151.99% 167.66% 70.86% 92.82% 70.19% 18.49% 17.95% 19.93% 10.37%
EBITDA Growth
-56.34% -4.97% 34.00% -5.69% -68.12% -220.93% -8.22% 35.46% 97.98% -9,351.29%
EBIT Growth
-58.22% -6.25% 30.00% -34.79% -46.60% -225.57% -8.25% 25.61% 64.92% -369.34%
NOPAT Growth
-58.22% -6.25% 30.00% -34.79% -46.60% -228.38% -11.46% 30.64% 63.77% -387.74%
Net Income Growth
-57.73% -5.96% 31.59% -53.11% -21.66% -286.51% 27.68% -4.68% 67.26% -403.97%
EPS Growth
-36.80% 4.68% 39.26% -44.44% -13.29% -236.42% 36.15% -1.72% 68.08% -394.69%
Operating Cash Flow Growth
-64.52% 2.95% 44.86% 3.88% -61.96% 222.24% -174.91% -118.67% 169.83% 34.86%
Free Cash Flow Firm Growth
-73.68% 4.71% -25.64% -67.98% -998.77% 87.96% -696.92% 84.69% 48.51% 131.48%
Invested Capital Growth
179.25% 14.22% 237.36% 145.63% 1,083.51% -6.76% 77.91% 0.00% 1.31% -16.38%
Revenue Q/Q Growth
48.70% 26.51% 24.40% 13.93% 21.09% 12.93% 0.42% 3.95% 3.90% 2.47%
EBITDA Q/Q Growth
-4.68% 1.93% 13.16% -13.77% -49.73% -84.86% 25.54% 18.73% 86.90% -3,167.46%
EBIT Q/Q Growth
-5.18% 1.58% 11.07% -19.77% -25.01% -69.59% 21.47% 11.94% 19.18% -320.14%
NOPAT Q/Q Growth
-5.18% 1.58% 11.07% -19.77% -25.01% -71.06% 18.45% 14.74% 19.18% -336.61%
Net Income Q/Q Growth
-5.02% 1.66% 11.87% -22.53% 1.32% -80.46% 24.92% 12.96% 27.64% -380.69%
EPS Q/Q Growth
-1.79% 5.78% 13.16% -22.22% 4.71% -78.10% 29.27% 14.08% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.87% 2.37% 26.88% -0.13% -28.04% 61,302.69% -403.01% 25.52% 12.63% -9.65%
Free Cash Flow Firm Q/Q Growth
-5.49% 4.43% -15.71% -11.71% -757.30% 86.60% -0.33% 41.75% -104.61% 101.32%
Invested Capital Q/Q Growth
14.35% -1.64% 44.03% 18.94% 617.25% 3.10% 4.91% 0.00% 0.00% -16.85%
Profitability Metrics
- - - - - - - - - -
Gross Margin
37.87% 54.52% 70.56% 74.33% 75.27% 76.24% 74.04% 68.27% 70.49% 69.55%
EBITDA Margin
-381.68% -159.00% -39.21% -24.25% -21.15% -39.87% -36.42% -19.93% -0.34% -28.79%
Operating Margin
-403.35% -170.08% -44.48% -35.09% -26.68% -51.48% -48.42% -28.48% -8.60% -38.01%
EBIT Margin
-403.35% -170.08% -44.48% -35.09% -26.68% -51.03% -46.62% -29.41% -8.60% -36.58%
Profit (Net Income) Margin
-400.14% -168.26% -43.01% -38.54% -24.32% -55.22% -33.71% -29.91% -8.17% -37.29%
Tax Burden Percent
100.00% 100.00% 99.84% 100.05% 52.43% 99.34% 70.70% 98.57% 101.19% 99.30%
Interest Burden Percent
99.20% 98.93% 96.85% 109.77% 173.86% 108.93% 102.26% 103.20% 93.83% 102.68%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-630.85% -424.96% -127.57% -64.50% -10.37% -19.10% -15.88% -8.60% -3.10% -16.34%
ROIC Less NNEP Spread (ROIC-NNEP)
-614.84% -408.83% -118.86% -49.64% -62.81% -71.02% -15.58% -20.25% -6.13% -33.49%
Return on Net Nonoperating Assets (RNNOA)
579.60% 374.46% 100.83% 35.34% -3.99% -17.31% -6.69% -11.89% -3.50% -20.75%
Return on Equity (ROE)
-51.25% -50.51% -26.74% -29.16% -14.35% -36.41% -22.57% -20.49% -6.60% -37.09%
Cash Return on Invested Capital (CROIC)
-725.38% -438.23% -236.11% -148.77% -179.20% -12.11% -71.95% -8.60% -4.40% 1.50%
Operating Return on Assets (OROA)
-47.00% -45.61% -24.25% -15.03% -9.30% -18.06% -14.78% -9.84% -3.39% -16.28%
Return on Assets (ROA)
-46.63% -45.13% -23.45% -16.50% -8.47% -19.54% -10.68% -10.01% -3.22% -16.60%
Return on Common Equity (ROCE)
-51.25% -50.51% -26.74% -29.16% -14.35% -36.41% -22.57% -20.49% -6.60% -37.09%
Return on Equity Simple (ROE_SIMPLE)
-48.28% -49.87% -21.98% -25.72% -9.31% -36.84% -19.57% -20.49% -6.49% -42.83%
Net Operating Profit after Tax (NOPAT)
-111 -118 -83 -112 -164 -537 -599 -415 -151 -734
NOPAT Margin
-282.34% -119.05% -31.14% -24.56% -18.68% -36.03% -33.90% -19.93% -6.02% -26.61%
Net Nonoperating Expense Percent (NNEP)
-16.00% -16.13% -8.70% -14.85% 52.45% 51.92% -0.30% 11.65% 3.04% 17.15%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -7.61% -2.65% -14.31%
Cost of Revenue to Revenue
62.13% 45.48% 29.44% 25.67% 24.73% 23.76% 25.96% 31.73% 29.51% 30.45%
SG&A Expenses to Revenue
146.94% 77.38% 40.97% 39.17% 40.22% 32.28% 45.34% 31.83% 32.01% 28.34%
R&D to Revenue
86.00% 33.68% 15.83% 14.81% 15.94% 37.15% 21.82% 18.91% 17.08% 15.63%
Operating Expenses to Revenue
441.22% 224.60% 115.04% 109.42% 101.95% 127.72% 122.46% 96.74% 79.10% 107.56%
Earnings before Interest and Taxes (EBIT)
-159 -169 -118 -159 -234 -761 -824 -613 -215 -1,009
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-151 -158 -104 -110 -185 -595 -644 -415 -8.40 -794
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.72 4.32 12.09 11.39 5.25 8.91 4.41 2.89 4.25 4.33
Price to Tangible Book Value (P/TBV)
2.72 4.34 12.68 12.22 0.00 132.20 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
22.55 14.57 23.65 17.06 13.70 13.36 7.59 4.22 5.35 3.77
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
22.63 38.49 58.61 29.76 4.34 7.52 3.15 2.19 3.09 2.95
Enterprise Value to Revenue (EV/Rev)
14.92 11.50 22.07 16.11 14.41 13.68 8.60 5.08 6.05 4.38
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 149.54 0.00 0.00 96.89 57.42
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 179.52
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.02 0.02 0.01 1.01 0.41 1.04 0.79 0.79 0.80 1.14
Long-Term Debt to Equity
0.02 0.02 0.01 1.01 0.41 0.90 0.79 0.79 0.79 1.03
Financial Leverage
-0.94 -0.92 -0.85 -0.71 0.06 0.24 0.43 0.59 0.57 0.62
Leverage Ratio
1.10 1.12 1.14 1.77 1.69 1.86 2.11 2.05 2.05 2.24
Compound Leverage Factor
1.09 1.11 1.10 1.94 2.95 2.03 2.16 2.11 1.93 2.30
Debt to Total Capital
1.81% 1.61% 0.85% 50.30% 29.28% 50.92% 44.28% 44.28% 44.53% 53.17%
Short-Term Debt to Total Capital
0.05% 0.05% 0.03% 0.00% 0.03% 6.89% 0.00% 0.00% 0.88% 4.86%
Long-Term Debt to Total Capital
1.76% 1.56% 0.81% 50.30% 29.25% 44.02% 44.28% 44.28% 43.65% 48.31%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
98.19% 98.39% 99.15% 49.70% 70.72% 49.08% 55.72% 55.72% 55.47% 46.83%
Debt to EBITDA
-0.04 -0.03 -0.04 -6.25 -5.11 -3.90 -3.76 -5.82 -300.49 -3.43
Net Debt to EBITDA
2.00 1.93 4.03 3.95 -3.36 -0.81 -2.78 -4.30 -207.96 -2.13
Long-Term Debt to EBITDA
-0.04 -0.03 -0.04 -6.25 -5.11 -3.37 -3.76 -5.82 -294.54 -3.12
Debt to NOPAT
-0.05 -0.05 -0.05 -6.17 -5.79 -4.32 -4.04 -5.82 -16.78 -3.72
Net Debt to NOPAT
2.70 2.58 5.07 3.90 -3.81 -0.89 -2.98 -4.30 -11.61 -2.30
Long-Term Debt to NOPAT
-0.05 -0.05 -0.05 -6.17 -5.78 -3.73 -4.04 -5.82 -16.45 -3.38
Altman Z-Score
11.78 17.80 46.92 5.38 5.61 4.04 1.75 1.04 2.07 0.78
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
12.19 10.87 7.15 9.02 2.34 3.47 2.38 2.38 2.32 2.15
Quick Ratio
11.67 10.41 6.62 8.59 1.92 3.27 1.91 1.91 1.91 1.76
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-128 -122 -153 -257 -2,829 -341 -2,714 -415 -214 67
Operating Cash Flow to CapEx
-667.28% -875.81% -147.95% -45.93% -64.67% 28.64% -52.74% -118.00% 125.21% 116.33%
Free Cash Flow to Firm to Interest Expense
-21,338.77 -572.80 -744.09 -7.00 -14.20 -5.01 -145.86 -21.16 -11.00 2.49
Operating Cash Flow to Interest Expense
-22,336.17 -610.64 -348.17 -1.87 -0.56 2.01 -5.49 -11.39 8.03 7.79
Operating Cash Flow Less CapEx to Interest Expense
-25,683.50 -680.36 -583.51 -5.95 -1.43 -5.00 -15.91 -21.04 1.62 1.09
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.12 0.27 0.55 0.43 0.35 0.35 0.32 0.33 0.39 0.45
Accounts Receivable Turnover
12.50 14.77 15.22 12.67 9.98 8.20 9.03 13.19 13.82 12.19
Inventory Turnover
4.58 6.69 4.77 3.58 4.30 4.60 4.36 5.59 6.00 5.80
Fixed Asset Turnover
1.46 2.75 4.50 2.79 2.50 3.29 3.11 3.04 3.61 3.96
Accounts Payable Turnover
8.23 22.50 9.30 5.27 8.01 11.49 8.29 8.83 9.60 9.98
Days Sales Outstanding (DSO)
29.20 24.72 23.98 28.81 36.59 44.49 40.41 27.68 26.40 29.94
Days Inventory Outstanding (DIO)
79.66 54.55 76.58 101.97 84.95 79.31 83.75 65.27 60.80 62.96
Days Payable Outstanding (DPO)
44.36 16.22 39.26 69.27 45.57 31.77 44.01 41.35 38.04 36.58
Cash Conversion Cycle (CCC)
64.50 63.05 61.30 61.51 75.97 92.03 80.15 51.60 49.17 56.33
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
26 30 100 246 2,912 2,715 4,830 4,830 4,893 4,092
Invested Capital Turnover
2.23 3.57 4.10 2.63 0.56 0.53 0.47 0.43 0.51 0.61
Increase / (Decrease) in Invested Capital
17 3.70 70 146 2,666 -197 2,115 0.00 63 -801
Enterprise Value (EV)
588 1,143 5,870 7,320 12,630 20,409 15,198 10,584 15,127 12,089
Market Capitalization
889 1,448 6,291 7,755 12,007 19,930 13,412 8,797 13,379 10,399
Book Value per Share
$3.39 $3.09 $4.35 $5.54 $17.62 $14.86 $17.66 $17.13 $17.39 $12.98
Tangible Book Value per Share
$3.39 $3.08 $4.14 $5.16 ($0.45) $1.00 ($7.31) ($7.09) ($6.15) ($5.26)
Total Capital
333 341 525 1,370 3,235 4,555 5,462 5,462 5,671 5,130
Total Debt
6.02 5.49 4.45 689 947 2,319 2,419 2,419 2,525 2,727
Total Long-Term Debt
5.85 5.32 4.27 689 946 2,005 2,419 2,419 2,475 2,478
Net Debt
-301 -306 -420 -435 623 479 1,786 1,786 1,748 1,689
Capital Expenditures (CapEx)
20 15 48 150 173 476 194 189 125 181
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-7.57 -8.05 -5.44 -32 -5.38 40 -63 -63 -48 50
Debt-free Net Working Capital (DFNWC)
299 303 419 1,092 318 1,880 570 570 730 1,088
Net Working Capital (NWC)
299 303 419 1,092 317 1,565 570 570 680 839
Net Nonoperating Expense (NNE)
46 49 32 64 49 286 -3.35 208 54 295
Net Nonoperating Obligations (NNO)
-301 -306 -420 -435 623 479 1,786 1,786 1,748 1,689
Total Depreciation and Amortization (D&A)
8.54 11 14 49 48 166 180 198 207 215
Debt-free, Cash-free Net Working Capital to Revenue
-19.20% -8.10% -2.05% -7.10% -0.61% 2.65% -3.54% -3.00% -1.92% 1.83%
Debt-free Net Working Capital to Revenue
758.95% 304.96% 157.63% 240.26% 36.32% 126.03% 32.23% 27.32% 29.19% 39.45%
Net Working Capital to Revenue
758.53% 304.78% 157.56% 240.26% 36.23% 104.97% 32.23% 27.32% 27.19% 30.42%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($1.71) ($1.63) ($0.99) ($1.43) ($0.64) ($5.61) $0.00 $0.00 ($1.13) ($5.59)
Adjusted Weighted Average Basic Shares Outstanding
97.45M 110.60M 120.94M 125.76M 443.90M 169.09M 0.00 0.00 180.14M 184.20M
Adjusted Diluted Earnings per Share
($1.71) ($1.63) ($0.99) ($1.43) ($0.64) ($5.61) $0.00 $0.00 ($1.13) ($5.59)
Adjusted Weighted Average Diluted Shares Outstanding
97.45M 110.60M 120.94M 125.76M 443.90M 169.09M 0.00 0.00 180.14M 184.20M
Adjusted Basic & Diluted Earnings per Share
($1.71) ($1.63) ($0.99) ($1.43) ($0.64) ($5.61) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
92.14M 102.34M 115.68M 122.21M 131.26M 151.14M 0.00 0.00 181.53M 185.76M
Normalized Net Operating Profit after Tax (NOPAT)
-111 -118 -83 -112 -164 -391 -585 -404 -150 -125
Normalized NOPAT Margin
-282.34% -119.05% -31.14% -24.56% -18.68% -26.19% -33.10% -19.40% -6.00% -4.55%
Pre Tax Income Margin
-400.14% -168.26% -43.08% -38.52% -46.38% -55.59% -47.68% -30.35% -8.07% -37.56%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-26,511.33 -793.50 -574.32 -4.33 -1.17 -11.20 -44.28 -31.22 -11.06 -37.35
NOPAT to Interest Expense
-18,557.93 -555.45 -402.02 -3.03 -0.82 -7.91 -32.19 -21.16 -7.74 -27.17
EBIT Less CapEx to Interest Expense
-29,858.67 -863.23 -809.66 -8.41 -2.04 -18.22 -54.70 -40.87 -17.47 -44.05
NOPAT Less CapEx to Interest Expense
-21,905.27 -625.17 -637.36 -7.11 -1.69 -14.92 -42.61 -30.81 -14.15 -33.87
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Exact Sciences

This table displays calculated financial ratios and metrics derived from Exact Sciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
14.61% 16.71% 23.82% 19.26% 20.12% 16.98% 5.82% 12.41% 12.78% 10.29%
EBITDA Growth
12.83% 59.34% 78.82% 76.59% 160.26% 81.78% -70.16% 200.95% -74.00% -5,922.42%
EBIT Growth
9.49% 43.77% 56.81% 52.89% 104.67% 45.52% -30.34% 65.87% -675.31% -1,191.77%
NOPAT Growth
14.79% 46.32% 56.44% 51.79% 105.40% 42.93% -38.40% 65.87% -629.01% -1,191.77%
Net Income Growth
10.89% 42.09% 59.02% 51.21% 100.53% 61.04% -48.65% 80.49% -4,915.62% -1,637.30%
EPS Growth
13.40% 44.62% 0.00% 52.13% 100.00% 0.00% 0.00% 80.00% 0.00% 0.00%
Operating Cash Flow Growth
-0.37% 311.77% 78.01% 264.86% 159.52% 33.65% -115.39% 6.61% 469.43% -32.33%
Free Cash Flow Firm Growth
84.52% 96.33% 63.13% 1,075.71% 1,598.38% -33.25% 2.06% -204.66% -202.34% 269.53%
Invested Capital Growth
4.91% 0.00% 2.39% 0.00% 0.00% 1.31% 1.84% 0.00% 0.00% -16.38%
Revenue Q/Q Growth
0.27% 5.72% 8.94% 3.26% 1.00% 2.95% 0.00% 9.68% 1.34% 0.67%
EBITDA Q/Q Growth
13.32% 23.49% 63.55% 3.14% 323.11% -123.13% 0.00% 157.46% -42.53% -5,456.61%
EBIT Q/Q Growth
10.20% 15.09% 38.09% 0.21% 108.90% -1,090.52% 0.00% 73.87% -50.07% -2,124.07%
NOPAT Q/Q Growth
13.49% 13.89% 35.15% 0.21% 109.68% -1,010.81% 0.00% 75.39% -50.07% -2,124.07%
Net Income Q/Q Growth
10.42% 14.13% 41.95% -9.27% 100.98% -6,367.76% 0.00% 85.66% -141.88% -2,161.18%
EPS Q/Q Growth
10.64% 14.29% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% -133.33% 0.00%
Operating Cash Flow Q/Q Growth
32.82% 227.15% -173.44% 362.79% -75.74% 185.49% 0.00% 230.07% 29.57% -66.07%
Free Cash Flow Firm Q/Q Growth
34.08% 74.21% -102.55% 2,933.26% 1.24% -102.29% 0.00% -2,927.75% 1.01% 103.80%
Invested Capital Q/Q Growth
0.00% 0.00% 1.83% -100.00% 0.00% 0.00% 0.00% -0.57% -1.20% -16.85%
Profitability Metrics
- - - - - - - - - -
Gross Margin
71.72% 57.66% 73.96% 74.76% 73.18% 60.55% 73.32% 72.85% 72.33% 60.17%
EBITDA Margin
-18.75% -13.57% -4.54% -4.26% 9.41% -2.11% -7.30% 3.82% 2.17% -115.39%
Operating Margin
-26.39% -21.50% -12.80% -12.37% 1.09% -10.49% -16.74% -3.75% -5.56% -122.84%
EBIT Margin
-28.03% -22.52% -12.80% -12.37% 1.09% -10.49% -15.76% -3.75% -5.56% -122.84%
Profit (Net Income) Margin
-28.44% -23.10% -12.31% -13.02% 0.13% -7.69% -17.29% -2.26% -5.40% -121.19%
Tax Burden Percent
97.95% 98.32% 102.29% 101.39% 76.13% 98.79% 101.67% 110.20% 102.16% 98.70%
Interest Burden Percent
103.57% 104.34% 94.04% 103.89% 15.23% 74.26% 107.91% 54.63% 94.99% 99.96%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 23.87% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-7.85% -6.49% -4.05% 0.00% 0.00% -3.77% -5.98% -2.76% -4.26% -52.81%
ROIC Less NNEP Spread (ROIC-NNEP)
-11.41% -8.99% -5.26% 0.00% 0.00% -3.90% -7.92% -2.47% -5.51% -67.42%
Return on Net Nonoperating Assets (RNNOA)
-5.15% -5.28% -2.76% 0.00% 0.00% -2.23% -4.65% -1.38% -2.93% -41.77%
Return on Equity (ROE)
-13.00% -11.77% -6.81% 0.00% 0.00% -6.00% -10.63% -4.14% -7.19% -94.58%
Cash Return on Invested Capital (CROIC)
-15.12% -8.60% -9.47% 0.00% 0.00% -4.40% -5.27% -205.45% -206.83% 1.50%
Operating Return on Assets (OROA)
-8.73% -7.54% -4.36% 0.00% 0.00% -4.13% -6.24% -1.47% -2.22% -54.66%
Return on Assets (ROA)
-8.85% -7.73% -4.19% 0.00% 0.00% -3.03% -6.85% -0.88% -2.15% -53.93%
Return on Common Equity (ROCE)
-13.00% -11.77% -6.81% 0.00% 0.00% -6.00% -10.63% -4.14% -7.19% -94.58%
Return on Equity Simple (ROE_SIMPLE)
-23.54% 0.00% -16.56% 0.00% 0.00% 0.00% -7.67% -5.48% -6.67% 0.00%
Net Operating Profit after Tax (NOPAT)
-97 -83 -54 -54 5.21 -47 -75 -18 -28 -613
NOPAT Margin
-18.48% -15.05% -8.96% -8.66% 0.83% -7.34% -11.71% -2.63% -3.89% -85.99%
Net Nonoperating Expense Percent (NNEP)
3.55% 2.49% 1.21% 0.00% 0.00% 0.13% 1.94% -0.29% 1.25% 14.61%
Return On Investment Capital (ROIC_SIMPLE)
- -1.52% - - - -0.84% - - - -11.96%
Cost of Revenue to Revenue
28.28% 42.34% 26.04% 25.24% 26.82% 39.45% 26.68% 27.15% 27.67% 39.83%
SG&A Expenses to Revenue
36.70% 21.69% 36.07% 38.25% 34.60% 19.73% 38.13% 28.87% 30.65% 16.77%
R&D to Revenue
17.36% 17.19% 15.84% 16.73% 17.74% 17.93% 17.35% 17.29% 14.13% 13.96%
Operating Expenses to Revenue
98.11% 79.16% 86.76% 87.13% 72.09% 71.04% 90.05% 76.61% 77.89% 183.01%
Earnings before Interest and Taxes (EBIT)
-147 -125 -77 -77 6.85 -68 -100 -26 -39 -876
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-98 -75 -27 -26 59 -14 -47 27 15 -823
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.89 2.89 3.87 0.00 0.00 4.25 3.99 2.44 3.92 4.33
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
2.87 4.22 5.49 7.36 5.12 5.35 4.93 2.98 4.68 3.77
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.56 2.19 2.82 0.00 0.00 3.09 2.87 1.92 2.91 2.95
Enterprise Value to Revenue (EV/Rev)
3.76 5.08 6.31 0.00 0.00 6.05 5.67 3.67 5.31 4.38
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 493.37 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 96.89 128.24 80.77 61.35 57.42
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 179.52
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.79 0.79 0.81 0.00 0.00 0.80 0.81 0.86 0.85 1.14
Long-Term Debt to Equity
0.79 0.79 0.80 0.00 0.00 0.79 0.71 0.78 0.77 1.03
Financial Leverage
0.45 0.59 0.52 0.00 0.00 0.57 0.59 0.56 0.53 0.62
Leverage Ratio
1.98 2.05 2.02 0.00 0.00 2.05 2.05 2.09 2.10 2.24
Compound Leverage Factor
2.05 2.14 1.90 0.00 0.00 1.52 2.21 1.14 2.00 2.23
Debt to Total Capital
44.28% 44.28% 44.78% 0.00% 0.00% 44.53% 44.66% 46.14% 45.97% 53.17%
Short-Term Debt to Total Capital
0.00% 0.00% 0.88% 0.00% 0.00% 0.88% 5.28% 4.20% 4.19% 4.86%
Long-Term Debt to Total Capital
44.28% 44.28% 43.90% 0.00% 0.00% 43.65% 39.38% 41.94% 41.78% 48.31%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
55.72% 55.72% 55.22% 0.00% 0.00% 55.47% 55.34% 53.86% 54.03% 46.83%
Debt to EBITDA
-4.73 -5.82 -8.56 0.00 0.00 -300.49 -74.78 140.77 -112.35 -3.43
Net Debt to EBITDA
-3.50 -4.30 -6.08 0.00 0.00 -207.96 -55.49 92.03 -70.35 -2.13
Long-Term Debt to EBITDA
-4.73 -5.82 -8.39 0.00 0.00 -294.54 -65.94 127.95 -102.11 -3.12
Debt to NOPAT
-4.96 -5.82 -7.33 0.00 0.00 -16.78 -14.76 -20.14 -16.24 -3.72
Net Debt to NOPAT
-3.67 -4.30 -5.20 0.00 0.00 -11.61 -10.96 -13.17 -10.17 -2.30
Long-Term Debt to NOPAT
-4.96 -5.82 -7.18 0.00 0.00 -16.45 -13.02 -18.31 -14.76 -3.38
Altman Z-Score
0.70 1.30 1.88 0.00 0.00 2.14 1.95 1.11 1.90 0.85
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.38 2.38 2.41 0.00 0.00 2.32 1.64 2.17 2.12 2.15
Quick Ratio
1.91 1.91 1.96 0.00 0.00 1.91 1.30 1.81 1.78 1.76
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-323 -83 -169 4,776 4,835 -111 -165 -4,998 -4,948 188
Operating Cash Flow to CapEx
-91.69% 71.40% -130.16% 289.23% 96.72% 196.34% -218.63% 298.51% 530.31% 57.88%
Free Cash Flow to Firm to Interest Expense
-61.64 -15.38 0.00 610.87 614.26 -14.10 -20.78 0.00 -515.06 19.63
Operating Cash Flow to Interest Expense
-7.82 9.62 0.00 12.85 3.10 8.84 -10.36 0.00 14.44 4.91
Operating Cash Flow Less CapEx to Interest Expense
-16.34 -3.85 0.00 8.40 -0.10 4.34 -15.10 0.00 11.72 -3.58
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.31 0.33 0.34 0.00 0.00 0.39 0.40 0.39 0.40 0.45
Accounts Receivable Turnover
9.84 13.19 10.86 0.00 0.00 13.82 11.52 9.90 10.17 12.19
Inventory Turnover
5.12 5.59 4.85 0.00 0.00 6.00 5.11 5.50 5.31 5.80
Fixed Asset Turnover
3.32 3.04 3.35 0.00 0.00 3.61 3.64 3.72 3.90 3.96
Accounts Payable Turnover
9.37 8.83 8.52 0.00 0.00 9.60 9.96 13.22 7.45 9.98
Days Sales Outstanding (DSO)
37.10 27.68 33.60 0.00 0.00 26.40 31.68 36.87 35.90 29.94
Days Inventory Outstanding (DIO)
71.30 65.27 75.20 0.00 0.00 60.80 71.46 66.38 68.69 62.96
Days Payable Outstanding (DPO)
38.96 41.35 42.84 0.00 0.00 38.04 36.65 27.61 48.97 36.58
Cash Conversion Cycle (CCC)
69.44 51.60 65.95 0.00 0.00 49.17 66.49 75.64 55.63 56.33
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
4,830 4,830 4,918 0.00 0.00 4,893 5,009 4,980 4,921 4,092
Invested Capital Turnover
0.43 0.43 0.45 0.00 0.00 0.51 0.51 1.05 1.09 0.61
Increase / (Decrease) in Invested Capital
226 0.00 115 -4,830 -4,830 63 90 4,980 4,921 -801
Enterprise Value (EV)
7,536 10,584 13,882 0.00 0.00 15,127 14,365 9,584 14,297 12,089
Market Capitalization
5,749 8,797 12,085 16,938 12,325 13,379 12,489 7,796 12,587 10,399
Book Value per Share
$17.20 $17.13 $17.51 $0.00 $0.00 $17.39 $17.18 $17.30 $17.38 $12.98
Tangible Book Value per Share
($7.12) ($7.09) ($6.50) $0.00 $0.00 ($6.15) ($6.04) ($5.52) ($5.53) ($5.26)
Total Capital
5,462 5,462 5,653 0.00 0.00 5,671 5,661 5,927 5,942 5,130
Total Debt
2,419 2,419 2,531 0.00 0.00 2,525 2,528 2,735 2,731 2,727
Total Long-Term Debt
2,419 2,419 2,481 0.00 0.00 2,475 2,229 2,486 2,482 2,478
Net Debt
1,786 1,786 1,797 0.00 0.00 1,748 1,876 1,788 1,710 1,689
Capital Expenditures (CapEx)
45 73 29 35 25 35 38 36 26 81
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-63 -63 -13 0.00 0.00 -48 82 86 37 50
Debt-free Net Working Capital (DFNWC)
570 570 722 0.00 0.00 730 734 1,033 1,058 1,088
Net Working Capital (NWC)
570 570 672 0.00 0.00 680 435 784 809 839
Net Nonoperating Expense (NNE)
52 45 20 27 4.42 2.28 36 -2.57 11 251
Net Nonoperating Obligations (NNO)
1,786 1,786 1,797 0.00 0.00 1,748 1,876 1,788 1,710 1,689
Total Depreciation and Amortization (D&A)
49 49 50 50 52 54 54 53 55 53
Debt-free, Cash-free Net Working Capital to Revenue
-3.12% -3.00% -0.58% 0.00% 0.00% -1.92% 3.23% 3.29% 1.39% 1.83%
Debt-free Net Working Capital to Revenue
28.40% 27.32% 32.80% 0.00% 0.00% 29.19% 28.96% 39.54% 39.32% 39.45%
Net Working Capital to Revenue
28.40% 27.32% 30.53% 0.00% 0.00% 27.19% 17.17% 30.01% 30.07% 30.42%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.84) ($0.72) $0.00 $0.00 $0.00 ($0.26) ($0.60) ($0.09) ($0.21) ($4.69)
Adjusted Weighted Average Basic Shares Outstanding
177.00M 176.35M 0.00 0.00 0.00 180.14M 182.35M 184.31M 184.80M 184.20M
Adjusted Diluted Earnings per Share
($0.84) ($0.72) $0.00 $0.00 $0.00 $0.00 $0.00 ($0.09) ($0.21) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
177.00M 176.35M 0.00 0.00 0.00 180.14M 184.53M 184.31M 184.80M 184.20M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
177.68M 0.00 0.00 0.00 0.00 181.53M 184.53M 184.77M 185.08M 185.76M
Normalized Net Operating Profit after Tax (NOPAT)
-92 -81 -54 -53 5.21 -47 -72 -13 -14 -27
Normalized NOPAT Margin
-17.68% -14.61% -8.95% -8.59% 0.83% -7.34% -11.23% -1.81% -2.05% -3.75%
Pre Tax Income Margin
-29.04% -23.50% -12.03% -12.85% 0.17% -7.79% -17.01% -2.05% -5.28% -122.78%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-28.01 -23.02 0.00 -9.84 0.87 -8.63 -12.65 0.00 -4.10 -91.51
NOPAT to Interest Expense
-18.46 -15.38 0.00 -6.89 0.66 -6.04 -9.40 0.00 -2.87 -64.05
EBIT Less CapEx to Interest Expense
-36.54 -36.49 0.00 -14.28 -2.33 -13.13 -17.39 0.00 -6.82 -100.00
NOPAT Less CapEx to Interest Expense
-26.99 -28.85 0.00 -11.33 -2.54 -10.54 -14.14 0.00 -5.59 -72.54
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Exact Sciences' Financials

When does Exact Sciences's fiscal year end?

According to the most recent income statement we have on file, Exact Sciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Exact Sciences' net income changed over the last 9 years?

Exact Sciences' net income appears to be on an upward trend, with a most recent value of -$1.03 billion in 2024, rising from -$157.80 million in 2015. The previous period was -$204.15 million in 2023.

What is Exact Sciences's operating income?
Exact Sciences's total operating income in 2024 was -$1.05 billion, based on the following breakdown:
  • Total Gross Profit: $1.92 billion
  • Total Operating Expenses: $2.97 billion
How has Exact Sciences revenue changed over the last 9 years?

Over the last 9 years, Exact Sciences' total revenue changed from $39.44 million in 2015 to $2.76 billion in 2024, a change of 6,895.6%.

How much debt does Exact Sciences have?

Exact Sciences' total liabilities were at $3.53 billion at the end of 2024, a 6.0% increase from 2023, and a 9,384.8% increase since 2015.

How much cash does Exact Sciences have?

In the past 9 years, Exact Sciences' cash and equivalents has ranged from $41.14 million in 2015 to $1.49 billion in 2020, and is currently $600.89 million as of their latest financial filing in 2024.

How has Exact Sciences' book value per share changed over the last 9 years?

Over the last 9 years, Exact Sciences' book value per share changed from 3.39 in 2015 to 12.98 in 2024, a change of 282.6%.

Remove Ads


This page (NASDAQ:EXAS) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners